ClinicalTrials.gg
Sign In
Drug

At-7519m clinical trials

Also written AT7519M.

studies test it
3
open now
0
in phase 3
0
first study started
2010

How each study uses at-7519m is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorisations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Development codes

AT7519M
3

Studies by the year they started

3 studies that test it; most in 2012 (2)

Studies that test at-7519m, by start year
YearStudies
20101
20122

By phase

A phase 1/2 study counts in both.

Phase 1
1
Phase 2
3

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Multiple Myeloma
1
Lymphoma, Mantle-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1

Who runs them

Industry 1 · Other 2

NCIC Clinical Trials Group (2) · Astex Pharmaceuticals, Inc. (1)

Studies

Open first, then newest update. How each study uses at-7519m is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 3

Codes

What other systems call at-7519m · ClinicalTrials.gg INT018640

  • Wikidata Q27294891at-7519mOne source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.